Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pilot Study of Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ Glioblastoma

NCT02209376 is registered in ClinicalTrials.gov with University of Pennsylvania as lead sponsor.

NCT NCT02209376
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02209376 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pilot Study of Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ Glioblastoma
Lead sponsor
University of Pennsylvania
Phase
Phase 1
Overall status
Terminated
Start date
November 18, 2014
Completion date
April 4, 2018
Enrollment
11 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

patients with residual or reccurent egfrviii+ glioma